The FDA issued a warning this week about a counterfeit version of Teva Pharmaceutical Industries’ Adderall 30 mg tablets being sold on the Internet.
Adderall is currently included on the FDA’s drug shortage list because of pharmaceutical ingredient supply issues. Teva continues to release product as it becomes available, according to the FDA.
Preliminary laboratory tests conducted by the FDA revealed that the counterfeit version of Teva’s Adderall 30 mg tablets contained the wrong active ingredients. Adderall, which is approved to treat attention-deficit/hyperactivity disorders and narcolepsy, contains four active ingredients: dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate. The counterfeit product contained tramadol and acetaminophen and none of the active ingredients of the authentic product, according to an FDA press release.
Authentic Adderall 30 mg tablets produced by Teva are round, scored tablets that are orange/peach in color and have the letters “dp” embossed on one side and “30” on the other side. The Adderall 30 mg tablets are packaged only in a 100-count bottle with the National Drug Code (NDC) 0555-0768-02 listed.
The Adderall 30 mg product may be counterfeit if:
- The product comes in a blister package.
- There are misspellings on the package, for example, “NDS” instead of “NDC”; “Aspartrte” instead of “Aspartate”; and “Singel” instead of “Single.”
- The tablets are white in color, round in shape, and are smooth.
- The tablets have no markings on them.
The counterfeit Adderall tablets are round and white and do not have any type of markings. The counterfeit versions of Adderall should be considered as unsafe, ineffective and potentially harmful.
Photos of Adderall to use as comparison can be found on the FDA site: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm305932.htm?source=govdelivery.
Adverse events or side effects from the suspect counterfeit Adderall should be reported to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program found at www.fda.gov/MedWatch/report.htm.